New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the internationally ...

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with ...

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

If you continue to have this issue please contact [email protected]. Adults who had an above-average BMI trajectory as children had an increased risk for COPD after age 40 years.